BerandaATAI • NASDAQ
add
ATAI Life Sciences NV
$1,47
Setelah Jam Perdagangan Normal:(0,68%)+0,0100
$1,48
Tutup: 1 Mei, 17.59.00 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$1,50
Rentang hari
$1,46 - $1,53
Rentang tahun
$1,03 - $2,57
Kapitalisasi pasar
293,70Â jt USD
Volume Rata-Rata
1,72Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | -5,00Â rb | -127,78% |
Biaya operasional | 29,34Â jt | -12,62% |
Laba bersih | -38,96Â jt | -112,98% |
Margin laba bersih | 779,16Â rb | 866,72% |
Penghasilan per saham | -0,24 | -100,00% |
EBITDA | -29,12Â jt | 12,97% |
Tarif pajak efektif | 1,81% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 62,33Â jt | -65,23% |
Total aset | 159,39Â jt | -45,69% |
Total liabilitas | 42,83Â jt | -12,87% |
Total ekuitas | 116,55 jt | — |
Saham yang beredar | 198,31 jt | — |
Harga terhadap nilai buku | 2,17 | — |
Tingkat pengembalian aset | -41,11% | — |
Tingkat pengembalian modal | -46,44% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -38,96Â jt | -112,98% |
Kas dari operasi | -24,30Â jt | -10,62% |
Kas dari investasi | 6,56Â jt | 897,08% |
Kas dari pembiayaan | 154,00Â rb | 101,82% |
Perubahan kas bersih | -17,46Â jt | 44,50% |
Arus kas bebas | -1,72Â jt | 86,74% |
Tentang
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Didirikan
2018
Situs
Karyawan
54
